Related Experiment Videos
Ototoxicity associated with intravenous bisphosphonate administration
I R Reid1, D A Mills, D J Wattie
1Department of Medicine, University of Auckland, New Zealand.
Calcified Tissue International
|June 1, 1995
Abstract:
The development of ototoxicity in association with intravenous pamidronate treatment of Paget's disease is described. The patient developed hearing loss, vertigo, and tinnitus which were exacerbated by subsequent infusions. This potentially serious drug side-effect does not appear to have been reported previously in patients with Paget's disease.
Insights
Pamidronate treatment for Paget
Area of Science:
- Ototoxicity and Pharmacology
- Bone Metabolism and Therapeutics
Background:
- Paget's disease of bone is a chronic condition affecting bone remodeling.
- Intravenous bisphosphonates, such as pamidronate, are used to manage Paget's disease.
Observation:
- A patient undergoing intravenous pamidronate treatment for Paget's disease experienced ototoxicity.
- Symptoms included hearing loss, vertigo, and tinnitus, worsening with further infusions.
Findings:
- This case report details the onset of ototoxicity linked to pamidronate therapy in Paget's disease.
- The observed ototoxic effects were directly correlated with pamidronate administration.
Implications:
- This highlights a previously unreported potential adverse effect of pamidronate in Paget's disease patients.
- Clinicians should monitor for auditory and vestibular symptoms during pamidronate treatment.
- Further research is warranted to understand the mechanism and incidence of pamidronate-induced ototoxicity.